CAS Name: (11b,17b)-9-Fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one
Fluoxymesterone is a 17-alpha-alkylated oral anabolic-androgenic steroid. Halogenation at position 9 increases the pharmacologic activity per unit weight compared to testosterone when given orally and reduces aromatization. It is a strong androgen with limited anabolic activity. Fluoxymesterone can be reduced by 5-alpha reductase into DHT and some of it’s androgenic activity may be caused not by fluoxymesterone itself, but to its metabolite DHT.
Fluoxymesterone used in hypogonadal males to induce normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Effects also include growth and maturation of prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution. Therefore, main indications for fluoxymesterolone are: primary hypogonadism (congenital or acquired) – testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy; hypogonadotropic hypogonadism (congenital or acquired) – idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
Metastatic mammary cancer – may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries.